Assistance Publique Hôpitaux de Paris
Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patients remain disabled at 3 months. Reperfusion rates after MT are critical to determine functional outcome. However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.
Stroke, Acute
Stroke, Ischemic
Glenzocimab
Placebo
Phase 2
Phase 3
Study Type : | Interventional |
Estimated Enrollment : | 260 participants |
Masking : | Quadruple |
Primary Purpose : | Treatment |
Official Title : | Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study |
Actual Study Start Date : | October 10, 2022 |
Estimated Primary Completion Date : | October 10, 2025 |
Estimated Study Completion Date : | October 10, 2026 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo |
Drug: Placebo |
Experimental: Glenzocimab |
Drug: Glenzocimab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.